Navigation Links
ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
Date:1/18/2008

- Irish and UK Blood services continue pre-adoption clinical evaluation of

filter - Recent case of vCJD now means that all the population is susceptible to

the disease - Increased concerns over "second wave" of vCJD in individuals with much

longer incubation times

- P-Capt(R) prion reduction filter still the only proven method of

protecting against potential transmission of the disease in blood - ProMetic and MacoPharma gearing up for implementation in watershed year

for the product

CAMBRIDGE, UK and LILLE, France, Jan. 18 /PRNewswire-FirstCall/ - The successful completion of two human clinical studies performed on volunteers using the P-Capt(R) prion reduction filter for red cell concentrates has been announced by ProMetic Life Sciences Inc. ("ProMetic") and MacoPharma. The clinical studies evaluated the effect of the filter on units of red cell concentrate collected from human volunteers, to ensure that the use of the filter had no negative effect on the red blood cells themselves. Data demonstrated no negative impact.

"These studies represent the first use of the P-Capt(R) prion filter in humans and the results demonstrate that not only is the product effective in reducing the risk of transmission of variant Creutzfeldt-Jakob disease ("vCJD") by blood transfusion but also there is no impact of the treatment on the blood itself," stated Mr. Christophe Vinzia, MacoPharma's Director of Business Development. "This represents a major milestone and we anticipate the positive results will encourage early adoption of the product in the UK and Ireland".

This latest news comes after reports of a previously unseen 'vv' genotype individual contracting vCJD. "Reports of the vv genotype individual now mean that any individual is susceptible to contracting vCJD," commented Dr. Peter Edwardson, ProMetic's Vi
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Thera, Inc.,announced today that the United States Patent ... "Protein-fragment Complementation,Assays (PCA) in whole animals: applications to ... gene therapy." This is the,twelfth patent issued for ... a method for detecting protein-protein,interactions in living cells ...
... Dec. 12 Genaera,Corporation (Nasdaq: GENR ) today ... Genaera, is scheduled to present at the 2007,RBC Capital ... Capital Markets, panel discussion of diabetes and obesity, entitled,"The ... place in,New York on Thursday, December 13 at 10:00 ...
... (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ) of Albuquerque, ... (New Mexico Tech at, http://www.nmt.edu ) reached an ... development of specialized image recognition technology as,part of ... early,detection of lung cancer., New Mexico Tech, ...
Cached Biology Technology:Odyssey Thera Granted U.S. Patent for Animal Imaging 2Biomoda Announces Collaborative Agreement With New Mexico Tech 2
(Date:4/17/2014)... eight hundred births, Down syndrome - or trisomy 21 ... disability. It results from a chromosomal abnormality where cells ... 21 (1% of the human genome). A study conducted ... of Genetic Medicine and Development at the University of ... , shed light on how the extra chromosome 21 ...
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... implicated in many serious conditions such as heart disease, ... for drug therapies. Unfortunately, there is still much scientists ... provides fresh and unexpected insight into the structure of ... β-subunit molecules - which are responsible for ,fine-tuning, the ... the most recent edition of the Journal of ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... , ,Mathematical models continue to play a major ... and control of malaria, a life-threatening parasitic disease ... Although existing models have advanced our understanding of ... new challenges., The National Institute for Mathematical and ...
... JOLLA, CA January 18, 2011 Using chemical compounds ... clever application of ultraviolet light, a Scripps Research Institute team ... to test for biomedical potential. Already, one of the compounds ... and fighting inflammation. With the report of their ...
... how the hormones progesterone and estrogen interact to increase ... a novel finding that may explain why postmenopausal women ... at increased risk of breast cancer. The discovery ... the increased production of the protein amphiregulin, which binds ...
Cached Biology News:Malaria modeling and control focus of workshop 2Scripps Research team creates new synthetic compound with HIV-fighting promise 2Scripps Research team creates new synthetic compound with HIV-fighting promise 3Researchers unlock how progesterone increases breast cancer risk 2